Med Onc at UKE Hamburg. @myESMO #ESMOYOC member, former @myESMO fellow. GU cancer specialist. Focus early phase trials 🎯💊 / translational research 🧬🧫🔬.
👉In case you missed this
Preclinical patient-derived modeling of castration-resistant prostate cancer facilitates individualized assessment of homologous recombination repair deficient disease
🔗https://t.co/vL400O6hQa
#HomologousRecombinationRepair#Olaparib#PARPi#PCSM
Job for a clinical fellow helping with oncology trials @Newcastle_ECMC@Nuth_OHR.
All previous incumbents have enjoyed themselves, built CVs and practiced baking amongst other skills
https://t.co/JtxA4mseJV
#ESMO22#ESMOYOC@myESMO Resilience Task Force kindly invites you to attend the Special Session tomorrow at 10 AM in La Serre - Hall 6 - level 2
👉Sharing strategies and coaching-style exercise to 🚀your own wellbeing and resilience for oncology professionals
@OncoAlert#ESMORTF
#ESMOTAT22 Virtual Lounge exploring 'How to become an expert in early phase trials & drug discovery research' w/ Timothy Yap, @rillepihlak & @OingC1 - your chance to discuss & exchange w/ peers & experts. Open to all event participants.
⏰ 7 Mar, 19:30 CET
https://t.co/PvKYNXPm5G
Elena Castro #emuc21 describes the DDR biomarker for PARPi in prostate cancer. BRCA1/2 are the most relevant DNA alterations. ctDNA is an attractive alternative to archived tissue. DDR alterations occur early. PARPi has an important role in prostate cancer @ChrisSweens1
💥 So excited about the upcoming #ESMOYOC sessions at #ESMOasiaweek21:
🗓 Sun 21/11 - Adapting data from practice-changing studies into daily practice in Asia: @LoiSher@herbloong
🗓 Mon 22/11 - Running clinical trials in Asia: @TonyMok9
Hope to see you there. Don’t miss it!
The #ESMOYOC virtual mentorship programme is open for applications. It's a great opportunity to be matched with @myESMO Leader for a 1:1 mentorship 12-months programme. Applications are open until Nov 21st.
👇https://t.co/14Hwa8u0Eu
Join me and @iamdonnagraham discussing the impact of Covid19 on early phase trials tomorrow @myESMO#MAP2021 conference!
Let's discuss the lessons learned and where can we go next? 🤓👩🏫
PS! #MAP2021 is free for all ESMO members😉
#ESMO21: Results from the SAKK 01/10 trial demonstrate favourable PFS and low toxicity with single-dose carboplatin and involved-node #radiotherapy.
👉https://t.co/jmDwfJq4RS
#tscsm#seminoma@robert_huddart